Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calluna Completes Phase 1 Study of CAL101 for Fibrotic Inflammatory Diseases
Details : CAL101 is a first-in-class mAb that targets S100A4, a DAMP protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis.
Product Name : CAL101
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 23, 2024
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Two biotechs Merge to Form Calluna, with €75M in Hand to Focus on Immunotherapy Antibodies
Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.
Product Name : CAL101
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Idelalisib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $81.1 million
Deal Type : Series A Financing
Lead Product(s) : Idelalisib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
Details : Zydelig® (idelalisib) is approved in the U.S. for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.
Product Name : Zydelig
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2022
Lead Product(s) : Idelalisib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
